Protara Therapeutics (NASDAQ:TARA) Earns Overweight Rating from Analysts at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage on shares of Protara Therapeutics (NASDAQ:TARA - Free Report) in a research report released on Friday morning, Marketbeat.com reports. The firm issued an overweight rating on the stock.

Several other equities research analysts also recently issued reports on the company. Guggenheim restated a "buy" rating and set a $20.00 price objective on shares of Protara Therapeutics in a report on Friday, December 6th. HC Wainwright restated a "buy" rating and issued a $23.00 price target on shares of Protara Therapeutics in a research note on Thursday, March 6th. Finally, Lifesci Capital began coverage on shares of Protara Therapeutics in a report on Tuesday, March 11th. They issued an "outperform" rating and a $22.00 price target on the stock. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Protara Therapeutics has a consensus rating of "Buy" and a consensus price target of $22.50.

Protara Therapeutics Price Performance

TARA traded down $0.09 during trading hours on Friday, reaching $4.33. 127,112 shares of the stock traded hands, compared to its average volume of 784,935. Protara Therapeutics has a fifty-two week low of $1.60 and a fifty-two week high of $10.48. The company has a market cap of $89.33 million, a price-to-earnings ratio of -1.54 and a beta of 1.69. The firm's fifty day simple moving average is $4.39 and its two-hundred day simple moving average is $3.51.

Remove Ads

Protara Therapeutics (NASDAQ:TARA - Get Free Report) last announced its earnings results on Wednesday, March 12th. The company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.09. On average, research analysts predict that Protara Therapeutics will post -3.32 earnings per share for the current year.

Institutional Investors Weigh In On Protara Therapeutics

A number of institutional investors have recently made changes to their positions in the company. Oppenheimer & Co. Inc. lifted its stake in Protara Therapeutics by 40.8% during the third quarter. Oppenheimer & Co. Inc. now owns 179,125 shares of the company's stock worth $328,000 after purchasing an additional 51,944 shares during the last quarter. XTX Topco Ltd bought a new position in shares of Protara Therapeutics in the 3rd quarter worth about $60,000. Geode Capital Management LLC boosted its holdings in shares of Protara Therapeutics by 21.0% in the 3rd quarter. Geode Capital Management LLC now owns 170,040 shares of the company's stock valued at $311,000 after buying an additional 29,514 shares during the period. Bailard Inc. bought a new stake in shares of Protara Therapeutics during the 4th quarter valued at about $157,000. Finally, Commonwealth Equity Services LLC raised its stake in Protara Therapeutics by 90.4% during the fourth quarter. Commonwealth Equity Services LLC now owns 37,000 shares of the company's stock worth $195,000 after acquiring an additional 17,572 shares during the period. 38.13% of the stock is currently owned by institutional investors.

About Protara Therapeutics

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.